Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | EVP, North America Commercial | March 06, 2023 | March 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date March 06, 2023 · Filed March 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 165,381 |
Last balance in matching sequence
After 2023-03-07 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2023-03-06 · Sale · Disposed 19,355 · Balance 223,447 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $10.045, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 2 · 2023-03-07 · Sale · Disposed 58,066 · Balance 165,381 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.37 to $9.725, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $10.045, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.37 to $9.725, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2020 Filed Mar 5, 2020 13:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,399 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-016459 · doc4.xml · nonDerivative · entry 1 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,459.7 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 12:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 69,384 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014847 · doc4.xml · derivative · entry 1 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,384 Underlying: Ordinary Shares · 69,384 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 17,346 vesting on each of February 28, 2021, February 28, 2022, February 28, 2023 and February 28, 2024. F2 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 17,346 vesting on each of February 28, 2021, February 28, 2022, February 28, 2023 and February 28, 2024. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 10, 2020 Filed Feb 11, 2020 11:53 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 5,669 | $12.27 | $69,558.63 |
DisclosureSEC source: 0001209191-20-008162 · doc4.xml · nonDerivative · entry 2 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,060.7 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. Read SEC document |
| February 09, 2020 Filed Feb 11, 2020 11:53 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 13,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-008162 · doc4.xml · derivative · entry 3 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,270 Underlying: Ordinary Shares · 13,135 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 13,135 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F5 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 13,135 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2020 Filed Feb 11, 2020 11:53 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 13,135 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-008162 · doc4.xml · nonDerivative · entry 1 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,729.7 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 11:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,446 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-050262 · doc4.xml · derivative · entry 2 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,446 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on September 18, 2017, with 1,445 vesting on September 18, 2018 and 1,446 vesting on September 18, 2019. F3 · derivative.expiration_date: Restricted share units were granted on September 18, 2017, with 1,445 vesting on September 18, 2018 and 1,446 vesting on September 18, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 11:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,446 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-050262 · doc4.xml · nonDerivative · entry 1 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,594.7 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 18, 2019 Filed Mar 19, 2019 12:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 632 | $16.63 | $10,507.06 |
DisclosureSEC source: 0001209191-19-020156 · doc4.xml · nonDerivative · entry 2 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,148.7 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.5800 to $16.6800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2019 Filed Mar 19, 2019 12:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,179 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-020156 · doc4.xml · derivative · entry 3 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,179 Underlying: Ordinary Shares · 1,179 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 17, 2016, with 1,179 vesting on each of March 17, 2018, March 17, 2019 and March 17, 2020. F6 · derivative.expiration_date: Restricted share units were granted on March 17, 2016, with 1,179 vesting on each of March 17, 2018, March 17, 2019 and March 17, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 17, 2019 Filed Mar 19, 2019 12:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,179 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-020156 · doc4.xml · nonDerivative · entry 1 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,780.7 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 11:31 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-019326 · doc4.xml · derivative · entry 3 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,191 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 12, 2015, with 1,190 vesting on March 12, 2018 and 1,191 vesting on March 12, 2019. F6 · derivative.expiration_date: Restricted share units were granted on March 12, 2015, with 1,190 vesting on March 12, 2018 and 1,191 vesting on March 12, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 11:31 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 647 | $15.67 | $10,141.66 |
DisclosureSEC source: 0001209191-19-019326 · doc4.xml · nonDerivative · entry 2 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,601.7 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.6600 to $15.6911, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 11:31 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,191 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-019326 · doc4.xml · nonDerivative · entry 1 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,248.7 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 12:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 606 | $16.88 | $10,231.28 |
DisclosureSEC source: 0001209191-19-016083 · doc4.xml · nonDerivative · entry 2 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,057.7 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.755 to $17.130, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 12:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 41,791 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-017229 · doc4.xml · derivative · entry 1 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,791 Underlying: Ordinary Shares · 41,791 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 13,930 vesting on each of March 4, 2021 and March 4, 2022 and 13,931 vesting on March 4, 2023. F2 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 13,930 vesting on each of March 4, 2021 and March 4, 2022 and 13,931 vesting on March 4, 2023. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2019 Filed Mar 5, 2019 12:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,399 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016083 · doc4.xml · derivative · entry 3 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,799 Underlying: Ordinary Shares · 1,399 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021. F6 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2019 Filed Mar 5, 2019 12:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,399 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-016083 · doc4.xml · nonDerivative · entry 1 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,663.7 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 20:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,445 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-051774 · doc4.xml · derivative · entry 3 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,446 Underlying: Ordinary Shares · 1,445 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on September 18, 2017, with 1,445 vesting on September 18, 2018 and 1,446 vesting on September 18, 2019. F6 · derivative.expiration_date: Restricted share units were granted on September 18, 2017, with 1,445 vesting on September 18, 2018 and 1,446 vesting on September 18, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 20:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 625 | $23.71 | $14,816.88 |
DisclosureSEC source: 0001209191-18-051774 · doc4.xml · nonDerivative · entry 2 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,264.7 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The Reporting Person's sale of shares reported herein is matchable under Section 16(b) of the Securities and Exchange Act of 1934, as amended ("Section 16(b)"). The Reporting Person has made arrangements with the Issuer to voluntarily disgorge to the Issuer the Section 16(b) profit that resulted from the transaction reported herein. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.640 to $23.735, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 20:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,445 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-051774 · doc4.xml · nonDerivative · entry 1 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,889.7 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| August 03, 2018 Filed Aug 7, 2018 13:45 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | PurchaseOrdinary Shares | 2,000 | $21.92 | $43,840.00 |
DisclosureSEC source: 0001209191-18-045615 · doc4.xml · nonDerivative · entry 1 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,444.7 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 20:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 571 | $17.88 | $10,208.34 |
DisclosureSEC source: 0001209191-18-020858 · doc4.xml · nonDerivative · entry 2 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,444.7 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.83 to $17.925, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2018 Filed Mar 20, 2018 20:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,179 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-020858 · doc4.xml · derivative · entry 3 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,358 Underlying: Ordinary Shares · 1,179 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 17, 2016, with 1,179 vesting on each of March 17, 2018, March 17, 2019 and March 17, 2020. F5 · derivative.expiration_date: Restricted share units were granted on March 17, 2016, with 1,179 vesting on each of March 17, 2018, March 17, 2019 and March 17, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 17, 2018 Filed Mar 20, 2018 20:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,179 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-020858 · doc4.xml · nonDerivative · entry 1 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,015.7 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 20:26 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-019560 · doc4.xml · derivative · entry 3 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,191 Underlying: Ordinary Shares · 1,190 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 12, 2015, with 1,190 vesting on March 12, 2018 and 1,191 vesting on March 12, 2019. F5 · derivative.expiration_date: Restricted share units were granted on March 12, 2015, with 1,190 vesting on March 12, 2018 and 1,191 vesting on March 12, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 20:26 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 576 | $19.49 | $11,225.66 |
DisclosureSEC source: 0001209191-18-019560 · doc4.xml · nonDerivative · entry 2 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,836.7 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.46 to $19.50, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 20:26 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,190 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-019560 · doc4.xml · nonDerivative · entry 1 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,412.7 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 21:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Tax withholdingOrdinary Shares | 677 | $19.38 | $13,120.26 |
DisclosureSEC source: 0001209191-18-017198 · doc4.xml · nonDerivative · entry 2 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,222.7 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2018 Filed Mar 6, 2018 21:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,399 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-017198 · doc4.xml · derivative · entry 3 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,198 Underlying: Ordinary Shares · 1,399 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021. F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2018 Filed Mar 6, 2018 21:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,399 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-017198 · doc4.xml · nonDerivative · entry 1 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,899.7 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 21:18 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 39,405 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009182 · doc4.xml · derivative · entry 2 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,405 Underlying: Ordinary Shares · 39,405 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 13,135 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F4 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 13,135 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 21:18 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantStock Options (right to buy) · Derivative | 100,457 | $0.00 Strike: $18.61 | $0.00 |
DisclosureSEC source: 0001209191-18-009182 · doc4.xml · derivative · entry 1 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,457 Underlying: Ordinary Shares · 100,457 shares Expires 2028-02-08 F1 · derivative.exercise_date: Stock options were granted on February 9, 2018, with 33,485 vesting on each of February 9, 2020 and February 9, 2021 and 33,487 vesting on February 9, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.